Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Fibrotic diseases].

Vered Molina1, Miri Blank, Yehuda Shoenfeld

  • 1Department of Medicine E, Research Unit of Autoimmune Diseases, Chaim Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Ramat Gan, Israel.

Harefuah
|December 13, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise, autoimmune diseases and T-regulatory cells.

Journal of autoimmunity·2024
Same author

Helminth derivative tuftsin-phopshorylcholine to treat autoimmunity.

Autoimmunity reviews·2024
Same author

The contradictive findings between ultrasound, hysteroscopy and cytokines in women with nonhormonal IUDs suffering from menorrhagia: a prospective study.

Archives of gynecology and obstetrics·2024
Same author

Shared Pathogenicity Features and Sequences between EBV, SARS-CoV-2, and HLA Class I Molecule-binding Motifs with a Potential Role in Autoimmunity.

Clinical reviews in allergy & immunology·2023
Same author

Functional IgG Autoantibodies against Autonomic Nervous System Receptors in Symptomatic Women with Silicone Breast Implants.

Cells·2023
Same author

Anti-TPO-mediated specific features of the placenta immunohistochemical profile and possible mechanisms for fetal loss.

Clinical and experimental immunology·2023

Fibrosis, a complex scarring process, involves extracellular matrix overproduction in response to tissue damage. Developing targeted antifibrotic agents is crucial for treating fibrotic diseases like scleroderma.

Area of Science:

  • Fibrosis research
  • Pathologic scarring
  • Connective tissue disorders

Context:

  • Fibrosis involves extracellular matrix overproduction and scarring following tissue damage.
  • The process is driven by interactions between cell types and cytokines, with a shift towards profibrotic signals.
  • Key profibrotic agents include CD4+ lymphocytes, CD40 signaling, IL-4, TGF-β, and PDGF, counteracted by interferon-gamma.

Purpose:

  • To explore the molecular mechanisms underlying fibrosis formation.
  • To identify key molecular players in the fibrotic process.
  • To highlight the need for targeted antifibrotic therapies.

Summary:

  • Fibrosis is characterized by excessive extracellular matrix deposition, distinct from normal tissue repair due to environmental and overproduction factors.

Related Experiment Videos

  • Pathologies range from skin scarring and cirrhosis to organ-specific fibrosis in the heart, kidneys, and lungs.
  • Scleroderma serves as a key model for studying systemic fibrosis due to its progressive, multi-organ involvement.

    • Impact:

    • Current treatments using anti-inflammatory and immunosuppressive agents are often ineffective and can be harmful.
    • There is a critical need for novel antifibrotic agents that target the specific molecular pathways of fibrosis.
    • Advancing fibrosis research offers the potential for significant clinical improvements for patients with debilitating fibrotic diseases.